Immunovant Inc., a clinical-stage immunology company, is under investigation for potential breaches of fiduciary duty by its directors and officers, in connection with a private placement transaction. The investigation focuses on Immunovant's January 2025 transaction, where its controlling stockholder, Roivant Sciences Ltd., purchased approximately 16.9 million shares at $20.00 per share-a $3.48 discount to the prior day's closing price. This discount resulted in a benefit to Roivant of nearly $60 million, raising concerns about the fairness of the deal to other shareholders. The probe invites current Immunovant investors to provide information, emphasizing potential conflicts of interest and shareholder impact.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.